Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses

Introduction: The search for effective inhibitors to multiple infectious agents including influenza, smallpox and hemorrhagic fever viruses is an area of active research as many of these agents pose dramatic health and economic challenges to the human population. Many of these infectious agents are not only endemic threats in different parts of the globe, but are also considered to have the potential of being used as bioterrorism agents. Areas covered: This review focuses on inhibitors that are currently in use in the research community against specific emerging infectious agents and those that have bioterrorism potential. The paper provides information about the availability of FDA approved drugs, whenever applicable, and insights into the specific aspect of the agent life cycle that is affected by drug treatment, when known. Expert opinion: The key message that is conveyed in this review is that a combination of pathogen and host-based inhibitors may have to be used for successful control of viral replication to limit the development of drug resistance.

[1]  F. Hayden,et al.  Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[2]  Chi‐Huey Wong,et al.  An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. , 2002, Glycobiology.

[3]  Andrzej T Galecki,et al.  Prevention of influenza pneumonitis by sialic Acid-conjugated dendritic polymers. , 2002, The Journal of infectious diseases.

[4]  L. Yao,et al.  Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein , 2009, Applied Microbiology and Biotechnology.

[5]  Wei Zhang,et al.  Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. , 2009, Biochemical and biophysical research communications.

[6]  Robert Damoiseaux,et al.  A broad-spectrum antiviral targeting entry of enveloped viruses , 2010, Proceedings of the National Academy of Sciences.

[7]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[8]  M. Bray,et al.  Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. , 1999, The Journal of infectious diseases.

[9]  H. Klenk,et al.  Oligomerization of Ebola Virus VP30 Is Essential for Viral Transcription and Can Be Inhibited by a Synthetic Peptide* , 2003, Journal of Biological Chemistry.

[10]  Takao Kuroda,et al.  Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. , 2003, Glycobiology.

[11]  R. Frank,et al.  Identification of a PA-Binding Peptide with Inhibitory Activity against Influenza A and B Virus Replication , 2009, PloS one.

[12]  B. Moss,et al.  Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. , 2007, Virology.

[13]  M. Paulshock,et al.  Antiviral Activity of 1-Adamantanamine (Amantadine) , 1964, Science.

[14]  J. A. Comer,et al.  Chapare Virus, a Newly Discovered Arenavirus Isolated from a Fatal Hemorrhagic Fever Case in Bolivia , 2008, PLoS pathogens.

[15]  B. Hjelle,et al.  Characterization and NMR Solution Structure of a Novel Cyclic Pentapeptide Inhibitor of Pathogenic Hantaviruses , 2007, Chemical biology & drug design.

[16]  V. Martinelli,et al.  Mitoxantrone: benefits and risks in multiple sclerosis patients , 2009, Neurological Sciences.

[17]  E. De Clercq,et al.  Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. , 1983, Antiviral research.

[18]  I. Barr,et al.  Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses , 2012, Drugs.

[19]  M. Kinch,et al.  FGI-104: a broad-spectrum small molecule inhibitor of viral infection. , 2009, American journal of translational research.

[20]  Erik De Clercq Emerging antiviral drugs. , 2008, Expert opinion on emerging drugs.

[21]  C. Peng,et al.  Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. , 2010, Anti-cancer agents in medicinal chemistry.

[22]  E. Kern,et al.  In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. , 2006, Antiviral research.

[23]  K. Seiter Toxicity of the topoisomerase II inhibitors , 2005, Expert opinion on drug safety.

[24]  Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  L. Holland,et al.  Peramivir and its use in H1N1 influenza. , 2010, Drugs of today.

[26]  Yoshihiro Kawaoka,et al.  T-705 (favipiravir) activity against lethal H5N1 influenza A viruses , 2009, Proceedings of the National Academy of Sciences.

[27]  M. Bray,et al.  Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. , 2000, Antiviral research.

[28]  D. Smee,et al.  Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. , 2010, Antiviral research.

[29]  T. Wilt,et al.  Chemotherapy for hormone-refractory prostate cancer. , 2006, The Cochrane database of systematic reviews.

[30]  D. Smee,et al.  Identification of Novel Antipoxviral Agents: Mitoxantrone Inhibits Vaccinia Virus Replication by Blocking Virion Assembly , 2007, Journal of Virology.

[31]  E. De Clercq The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. , 2007, Antiviral research.

[32]  E. De Clercq,et al.  (S)-9-(2,3-Dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity , 1978, Science.

[33]  J. Gorchynski,et al.  Acute ascending paralysis presenting as an endocrine emergency. , 2009, American Journal of Emergency Medicine.

[34]  E. Reinherz,et al.  Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. , 2005, The Journal of clinical investigation.

[35]  C. García,et al.  Inhibition of Junín virus replication by small interfering RNAs , 2009, Antiviral Research.

[36]  S. M. Amberg,et al.  pH-Induced Activation of Arenavirus Membrane Fusion Is Antagonized by Small-Molecule Inhibitors , 2008, Journal of Virology.

[37]  R. Charrel,et al.  Arenaviruses other than Lassa virus. , 2003, Antiviral research.

[38]  J. Taubenberger,et al.  Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[40]  C. García,et al.  Inhibition of arenavirus infection by thiuram and aromatic disulfides. , 2010, Antiviral research.

[41]  A. Siddiqui,et al.  Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies , 2008, Virology.

[42]  E. De Clercq,et al.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds , 1991, Antimicrobial Agents and Chemotherapy.

[43]  R. Buller,et al.  Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. , 2004, Virology.

[44]  M. Kinch,et al.  Development of a broad-spectrum antiviral with activity against Ebola virus. , 2009, Antiviral research.

[45]  E. De Clercq Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections , 2001, Clinical Microbiology Reviews.

[46]  K. Nakai,et al.  Obstructive acute renal failure related to amantadine intoxication. , 2009, The American journal of emergency medicine.

[47]  D. Hruby,et al.  Tecovirimat for smallpox infections. , 2010, Drugs of today.

[48]  C. Peters,et al.  Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. , 1985, Vaccine.

[49]  Yasuo Suzuki,et al.  Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus , 1998, Glycoconjugate Journal.

[50]  K. Borden,et al.  An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. , 2010, Biochemical and biophysical research communications.

[51]  C. García,et al.  Characterization of Junín virus particles inactivated by a zinc finger-reactive compound. , 2009, Virus research.

[52]  S. Ludwig Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. , 2009, The Journal of antimicrobial chemotherapy.

[53]  E. Saphire,et al.  Ebolavirus glycoprotein structure and mechanism of entry. , 2009, Future virology.

[54]  C. Achete,et al.  Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus , 2009, Journal of Virology.

[55]  J. Tomassini,et al.  Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors , 1996, Antimicrobial agents and chemotherapy.

[56]  W. Garten,et al.  The role of myristoylation in the membrane association of the Lassa virus matrix protein Z , 2006, Virology Journal.

[57]  G. Ruthel,et al.  Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection , 2010, Antimicrobial Agents and Chemotherapy.

[58]  A. Kuehne,et al.  Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. , 1992, Intervirology.

[59]  S. M. Amberg,et al.  Identification of a Broad-Spectrum Arenavirus Entry Inhibitor , 2008, Journal of Virology.

[60]  R. Sidwell,et al.  Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. , 2008, Antiviral research.

[61]  G. Ruthel,et al.  Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection , 2009, Antimicrobial Agents and Chemotherapy.

[62]  S. Kunz,et al.  Targeting the Proteolytic Processing of the Viral Glycoprotein Precursor Is a Promising Novel Antiviral Strategy against Arenaviruses , 2009, Journal of Virology.

[63]  D. Smee,et al.  Treatment of Late Stage Disease in a Model of Arenaviral Hemorrhagic Fever: T-705 Efficacy and Reduced Toxicity Suggests an Alternative to Ribavirin , 2008, PloS one.

[64]  E. Vela,et al.  Genistein treatment of cells inhibits arenavirus infection. , 2008, Antiviral research.

[65]  S. Makino,et al.  Rift valley fever vaccines. , 2009, Vaccine.

[66]  Peter B Jahrling,et al.  Exotic emerging viral diseases: progress and challenges , 2004, Nature Medicine.

[67]  F. Geng,et al.  Mesoionic Heterocyclic Compounds as Candidate Messenger RNA Cap Analogue Inhibitors of the Influenza Virus RNA Polymerase Cap-Binding Activity , 2009, Antiviral chemistry & chemotherapy.

[68]  O. Ergonul Treatment of Crimean-Congo hemorrhagic fever. , 2008, Antiviral research.

[69]  D L Barnard,et al.  In vitro and in vivo influenza virus-inhibitory effects of viramidine. , 2005, Antiviral research.

[70]  John Steel,et al.  Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries , 2010, PLoS pathogens.

[71]  Ralph S. Baric,et al.  Novel Influenza Virus NS1 Antagonists Block Replication and Restore Innate Immune Function , 2008, Journal of Virology.

[72]  H. Horikawa,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1) during 2007–2009 Influenza Seasons, Japan , 2010, Emerging infectious diseases.

[73]  E. Saphire,et al.  Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. , 2009, Current opinion in structural biology.

[74]  D. Smee Progress in the Discovery of Compounds Inhibiting Orthopoxviruses in Animal Models , 2008, Antiviral chemistry & chemotherapy.

[75]  Takeshi Masuda,et al.  Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. , 2003, Bioorganic & medicinal chemistry letters.

[76]  Rafael Delgado,et al.  In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. , 2004, The Journal of infectious diseases.

[77]  J. Klingström,et al.  An Antibody against a Novel and Conserved Epitope in the Hemagglutinin 1 Subunit Neutralizes Numerous H5N1 Influenza Viruses , 2010, Journal of Virology.

[78]  D. A. Stein,et al.  Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers , 2006, PLoS pathogens.

[79]  A. Gronenborn,et al.  The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. , 2005, Mini reviews in medicinal chemistry.

[80]  Thorsten Wolff,et al.  Interplay between influenza A virus and the innate immune signaling. , 2010, Microbes and infection.

[81]  A. Lackenby,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.

[82]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[83]  B. Hjelle,et al.  Hantavirus infection. , 1998, Disease-a-month : DM.

[84]  P. Iversen,et al.  Advanced antisense therapies for postexposure protection against lethal filovirus infections , 2010, Nature Medicine.

[85]  M. Feinberg,et al.  Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases , 2005, Nature Medicine.

[86]  Richard S. Larson,et al.  Peptide Antagonists That Inhibit Sin Nombre Virus and Hantaan Virus Entry through the β3-Integrin Receptor , 2005, Journal of Virology.

[87]  Philip K. Russell,et al.  Hemorrhagic fever viruses as biological weapons: medical and public health management. , 2002, JAMA.

[88]  F. Linero,et al.  Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro , 2009, Virus Research.

[89]  C. Peters,et al.  Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. , 1999, Vaccine.

[90]  J. Taubenberger,et al.  Influenza: The Once and Future Pandemic , 2010, Public health reports.

[91]  Deborah Ferriola,et al.  Tyrosine kinase blockers: new hope for successful cancer therapy. , 2009, Anti-cancer agents in medicinal chemistry.

[92]  K. Spurgers,et al.  Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses , 2008, Antiviral Research.

[93]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[94]  L. Staudt,et al.  Active NF-kappaB signalling is a prerequisite for influenza virus infection. , 2004, The Journal of general virology.

[95]  M. Bray,et al.  3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. , 2002, Antiviral research.

[96]  Hung-Jen Liu,et al.  PI3K-Akt signaling and viral infection. , 2008, Recent patents on biotechnology.

[97]  H. Feldmann,et al.  Prospects for immunisation against Marburg and Ebola viruses , 2010, Reviews in medical virology.

[98]  R. Borchardt,et al.  9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity , 1987, Antimicrobial Agents and Chemotherapy.

[99]  G. Cristalli,et al.  Antiviral properties of deazaadenine nucleoside derivatives. , 2006, Current medicinal chemistry.

[100]  J. Williamson,et al.  Neuraminidase Inhibitors in Patients with Underlying Airways Disease , 2002, American journal of respiratory medicine : drugs, devices, and other interventions.

[101]  H. Klenk,et al.  Natural and synthetic sialic acid‐containing inhibitors of influenza virus receptor binding , 2003, Reviews in medical virology.

[102]  W. Ian Lipkin,et al.  Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever–Associated Arenavirus from Southern Africa , 2009, PLoS pathogens.

[103]  James R. Smith Oseltamivir in human avian influenza infection , 2010, The Journal of antimicrobial chemotherapy.

[104]  X. de Lamballerie,et al.  Arenaviruses. , 2007, Current topics in microbiology and immunology.

[105]  E. Declercq Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines. , 1980 .

[106]  J. Alimonti,et al.  In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. , 2007, The Journal of infectious diseases.

[107]  D. Smee,et al.  Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro , 2010, PloS one.

[108]  Hiroki Inoue,et al.  Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. , 2010, Journal of medicinal chemistry.

[109]  L. Harrison,et al.  Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. , 1998, The Journal of infectious diseases.

[110]  R. Borchardt,et al.  Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. , 1984, The Journal of biological chemistry.

[111]  J. Huggins,et al.  Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever , 1988, Antimicrobial Agents and Chemotherapy.

[112]  E. De Clercq Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines. , 1980, Methods and findings in experimental and clinical pharmacology.

[113]  D. Smee,et al.  Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. , 2009, The Journal of antimicrobial chemotherapy.

[114]  G. Yılmaz,et al.  The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[115]  K. Borden,et al.  Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. , 2006, The Journal of general virology.

[116]  T. Meyer,et al.  Inhibition of Marburg virus protein expression and viral release by RNA interference. , 2005, The Journal of general virology.

[117]  D. A. Stein,et al.  VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice , 2006, Antimicrobial Agents and Chemotherapy.

[118]  Paolo Ascenzi,et al.  Ebolavirus and Marburgvirus: insight the Filoviridae family. , 2008, Molecular aspects of medicine.

[119]  S. Cordo,et al.  Myristic acid analogs are inhibitors of Junin virus replication. , 1999, Microbes and infection.

[120]  I. Barr,et al.  Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. , 2010, Antiviral research.

[121]  Kevin F. Jones,et al.  Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses , 2005, Antiviral Research.

[122]  Xiao Yan Yang,et al.  Phase I Evaluation of the Safety and Pharmacokinetics of a Single-Dose Intravenous Injection of a Murine Monoclonal Antibody against Hantaan Virus in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.

[123]  R. K. Robins,et al.  Effect of 1-β-d-Ribofuranosyl-1,2,4-Triazole-3-Carboxamide (Virazole, ICN 1229) on Herpes and Vaccinia Keratitis and Encephalitis in Laboratory Animals , 1973, Antimicrobial Agents and Chemotherapy.

[124]  Brian D. Peyser,et al.  Identification of Essential Filovirion-associated Host Factors by Serial Proteomic Analysis and RNAi Screen* , 2010, Molecular & Cellular Proteomics.

[125]  M. Mendenhall,et al.  In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. , 2007, Antimicrobial agents and chemotherapy.

[126]  J. C. de la Torre,et al.  Myristoylation of the RING Finger Z Protein Is Essential for Arenavirus Budding , 2004, Journal of Virology.

[127]  R. Shaw,et al.  beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[128]  R. Webby,et al.  Mutations in the NS1 Protein of Swine Influenza Virus Impair Anti-Interferon Activity and Confer Attenuation in Pigs , 2005, Journal of Virology.

[129]  Mike Bray,et al.  Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.